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Background: Next generation sequencing provides clinical research scientists with direct read out of innumerable
variants, including personal, pathological and common benign variants. The aim of resequencing studies is to
determine the candidate pathogenic variants from individual genomes, or from family-based or tumor/normal
genome comparisons. Whilst the use of appropriate controls within the experimental design will minimize the
number of false positive variations selected, this number can be reduced further with the use of high quality whole
genome reference data to minimize false positives variants prior to candidate gene selection. In addition the use of
platform related sequencing error models can help in the recovery of ambiguous genotypes from lower coverage
data.
Description: We have developed a whole genome database of human genetic variations, Huvariome, determined
by whole genome deep sequencing data with high coverage and low error rates. The database was designed to
be sequencing technology independent but is currently populated with 165 individual whole genomes consisting
of small pedigrees and matched tumor/normal samples sequenced with the Complete Genomics sequencing
platform. Common variants have been determined for a Benelux population cohort and represented as genotypes
alongside the results of two sets of control data (73 of the 165 genomes), Huvariome Core which comprises 31
healthy individuals from the Benelux region, and Diversity Panel consisting of 46 healthy individuals representing 10
different populations and 21 samples in three Pedigrees. Users can query the database by gene or position via a
web interface and the results are displayed as the frequency of the variations as detected in the datasets. We
demonstrate that Huvariome can provide accurate reference allele frequencies to disambiguate sequencing
inconsistencies produced in resequencing experiments. Huvariome has been used to support the selection of
candidate cardiomyopathy related genes which have a homozygous genotype in the reference cohorts. This
database allows the users to see which selected variants are common variants (> 5% minor allele frequency) in the
Huvariome core samples, thus aiding in the selection of potentially pathogenic variants by filtering out common
variants that are not listed in one of the other public genomic variation databases. The no-call rate and the
accuracy of allele calling in Huvariome provides the user with the possibility of identifying platform dependent
errors associated with specific regions of the human genome.
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Conclusion: Huvariome is a simple to use resource for validation of resequencing results obtained by NGS
experiments. The high sequence coverage and low error rates provide scientists with the ability to remove false
positive results from pedigree studies. Results are returned via a web interface that displays location-based genetic
variation frequency, impact on protein function, association with known genetic variations and a quality score of
the variation base derived from Huvariome Core and the Diversity Panel data. These results may be used to identify
and prioritize rare variants that, for example, might be disease relevant. In testing the accuracy of the Huvariome
database, alleles of a selection of ambiguously called coding single nucleotide variants were successfully predicted
in all cases. Data protection of individuals is ensured by restricted access to patient derived genomes from the host
institution which is relevant for future molecular diagnostics.
Keywords: Medical genetics, Medical genomics, Whole genome sequencing, Allele frequency, CardiomyopathyBackground
Next-generation sequencing (NGS) provides scientists
with the ability to screen for genetic variants at a higher
density than genome wide screens with array based plat-
forms [1]. The choice of sequencing the whole genome
or only the exome, the latter comprising approximately
1% of the entire genome, depends on the type of re-
search question to be addressed. Exome sequencing
delivers information on the coding regions of the ge-
nome [2] and has been successfully applied, and con-
tinues to be applied, to determine the causative genetic
event in Mendelian inherited diseases [3]. Whole ge-
nome sequencing provides scientists with an unbiased
view of genetic variation of the genome including pro-
moters, intronic splicing regulators, regulatory regions
(enhancers, silencers), non-coding RNAs (microRNAs,
snoRNAs, lincRNA) and structural variation including
copy number [4]. There are 3 to 4 million SNVs per
human genome of which approximately 10% are novel
variants, some of which are false positives and may
confound the selection of disease causing variants [4].
Variants detected in other genomes are less likely to be
artifacts; hence the use of databases to store high qua-
lity personal variants will improve the detection of
pathogenic variants. The advent of whole genome and
exome sequencing tests, replacing the single variant
assay as clinical genetics tests and for cancer diagnosis
based on reduced costs, will require access to large
scale central databases to distinguish clinically relevant
variations from neutral polymorphisms [5]. The central
requirement for implementing NGS into clinical prac-
tice is to allow simple and secure access to databases
containing curated knowledge of variants scored as
clinically relevant pathogenic mutations with standar-
dized clinical reporting. Several existing projects that
support the detection of common deleterious variants
in the population include Online Mendelian Inheri-
tance in Man [6], dbSNP [7], Database of Genomic
Variants [8] and Human Gene Mutation Database [9].
SeattleSeq Annotation [10] and ENGINES [11] areboth web services for easy access to the genotypes
stored in dbSNP, and for annotation of variants for
both hg18 and hg19 genome builds. NGS catalog [12]
which is built on SeattleSeq provides scientists with an
integrated view of public literature derived variation
results, summarized by sequencing platform type (e.g.
RNAseq), technology platform (e.g. HiSeq2000) and
linked to the publication from which the results were
derived. ANNOVAR [13], a command line tool, is
popular with bioinformaticians and is used to annotate
experimentally derived variants with common and rare
variants derived from the popular sources (e.g. dbSNP),
the 1000 genomes project [14], and Exome Variant Ser-
ver [15], and to provide functional impact where ap-
propriate in coding regions. However, to the medical
research scientist the majority of these results have
been made available in the web application SNPnexus
[16], which delivers functional annotation of novel and
known variants and improved access via positional
mapping through contig or clone coordinates. Huva-
riome provides the user with whole genome allele fre-
quencies, their associated quality score (detection and
chance to detect the variant), gene based ranking and
integrated access to publicly available data for the de-
tection of common, rare and deleterious variants. The
functional impact of variants in Huvariome is provided
by the Complete Genomics (CG) annotation pipeline
[17]. The novelty of Huvariome is that it provides
rapid and simple access to SNV, short indels, and de
novo assembled regions of the genome at any position
in the genome with allelic frequencies and associated
error for position in the human genome. Huvariome
also delivers common variants from a small cohort of
Benelux genomes from unrelated individuals with no
disease association. In light of these developments we
have developed a simple application, Huvariome, which
goes beyond the current platforms with similar goals
[10,11] to enable efficient allelic frequencies searching
in both public and private genomes for clinical re-
search scientists.
Stubbs et al. Journal of Clinical Bioinformatics 2012, 2:19 Page 3 of 14
http://www.jclinbioinformatics.com/content/2/1/19Construction and content
Subjects
Standard for human subject and data protection
All records for the biological specimens are maintained
within the hospital health record management system
and an anonymized sample code was supplied with the
DNA and used to map the returned sequence data to
the appropriate sample information stored in the data-
base. All subjects whose whole genome sequence (WGS)
results are stored within the database were approved of
by the Institutional Review Board of the Erasmus MC,
Rotterdam, the Netherlands (MEC-2011-253, date of ap-
proval February 27th, 2011) in which patients gave writ-
ten informed consent according to institutional and
national guidelines. Formalized meta-data relating to the
individual from whom the genome was sequenced, but
with no name or hospital identification code, is stored
(Table 1), thus preventing the individual from being
identified from the database. In addition the variants
within a genome for the samples in Huvariome which
are not publicly available are not presented on the public
user interface to ensure that these individuals cannot be
identified by their genomic variation.
Next generation sequencing
Paired-end sequencing for all DNA samples was per-
formed with the Complete Genomics service provider
using a proprietary sequencing-by-ligation technology
[17]. Complete Genomics also performed primary data
analysis, including image analysis, base calling, align-
ment and variant calling. Reads were mapped to the
NCBI Build 36.1 reference genome using a fast algo-
rithm and initial mappings were expanded by local de
novo assembly on all regions of the genome that contain
single nucleotide variations (SNVs) relative to the refer-
ence genome [17]. Sequencing reads were mapped to
the reference genome with versions 1.1.0 to 1.12.0 of the
Complete Genomics Analysis (CGA) pipeline fromTable 1 Standardized parameters for meta-data
Parameter Description Limit
Age Age Variable
Gender Male , Female, other Fixed
Ethnicity HapMap groups Fixed
Country of origin (if known) UK, Netherlands, . . . Variable
Study Type Cancer, Family, Reference Fixed
Biomaterial Blood, Tissue, Cell line Fixed
Biomaterial Subtype PBMC, WBC, Heart, B-cell, . . . Variable
Biomaterial Source Peripheral vien, . . . Variable
Biomaterial Modification EBV transformed, . . . Variable
The Description defines the options that are available for each Parameter. A
parameter for which the Limit is fixed means that there are a fixed number of
possible values whereas one that is Variable is stored as any value (free text or
numeric).which the derived variant files include the SNVs, inserts
and deletions (indels), and substitutions (subs) with con-
fidence scores and explicit differentiation of “no-variant”
from “no-call”. Currently these data are shipped as bzip
format on 1.5 Tb discs and uploaded to the Department
of Bioinformatics IBM server. The resultant genomes are
at least 40X (~120 GB) mapped coverage with accurate
calls >95% for the genomes.
Development of the database
Informatics infrastructure
Huvariome is developed with an Oracle 11i 64-bit rela-
tional database (Enterprise Edition Release 11.2.0.1.0),
the code developed in Perl 5.8.8 and the graphical user
interface developed with PHP 5.3.3, and is available on
an Apache 2.2.3 server. The database is designed to store
all variation types detected by Complete Genomics and
are supplied in the variation results file (“VAR” file)
which includes SNVs, indels and subs up to ~100bp as
defined by the Complete Genomics Release Notes As-
sembly Software v2.0 [18]. Those variations that occur
in a gene (50UTR, 30UTR, exon and intron) are supplied
with additional annotation describing the associated
gene in the gene file. The VAR and gene files are loaded
into the Oracle database using a custom loader that was
developed to provide quality assurance upon upload and
to be easily adapted to accommodate changes in the an-
notation pipeline of Complete Genomics. The database
stores variants relative to a reference genome such that
only differences to the reference are listed, allowing for a
substantial reduction of data. Each genome is annotated
with a minimal set of required information detailing the
individual sample and the relationship with other sam-
ples (e.g. tumor versus paired normal and parents versus
children). This minimal information of the genome
source ensures that the propensity of variation to appear
in a subset of the data can be traced and allows users to
perform meta-analyses across the whole database to ra-
pidly identify cancer associated and family based va-
riants. Currently all genomes are mapped to NCBI build
36.3 and annotated using RefSeq data for gene and pro-
tein annotations, dbSNP version 130 [7], DGV [8] for
known variations and GenomeTraxTM (Biobase, Ger-
many) for multiple annotations including HGMD
Professional.
Development of the schema
Database design was developed to reflect, where pos-
sible, the original data tables supplied by Complete Ge-
nomics [18] to ensure the ability to store genomes as the
data output from the CGA pipeline advances with richer
annotation and improved quality measurements
included with the supplied data. Variation data, SNVs,
indels and subs, supplied in the VAR files are stored as
Table 2 Summary of huvariome genomes
Description Female (range) Male (range) All (range)
Gross mapping yield (Gb) 206 (160–280) 202 (168–249) 206 (160–280)
Fully called genome fraction 95.13% (91%/97%) 95.89% (94%/97%) 95.13% (91%/97%)
Partially called genome fraction 0.96% (0%/2%) 0.69% (0%/1%) 0.96% (0%/2%)
No-called genome fraction 3.91% (3%/7%) 3.42% (2%/5%) 3.91% (2%/7%)
SNP total count 3257897 (2966002–3396520) 3275018 (3056972–3495143) 3257897 (2966002–3495143)
SNP novel rate 6.71% (6%/7%) 6.78% (6%/9%) 6.71% (6%/9%)
Synonymous SNP 9239 (8668–9564) 9229 (8503–9821) 9239 (8503–9821)
Missense SNP 9046 (8348–9456) 9037 (8380–9574) 9046 (8348–9574)
Nonsense SNP 96 (86–117) 95 (77–110) 96 (77–117)
Nonstop SNP 24 (19–29) 22 (17–26) 24 (17–29)
INS total count 180040 (152082–208451) 190177 (160473–209226) 180040 (152082–209226)
INS novel rate 21.31% (19%/23%) 21.58% (19%/23%) 21.31% (19%/23%)
Frame-shifting INS 134 (113–157) 130 (95–152) 134 (95–157)
Frame-preserving INS 116 (96–132) 117 (98–130) 116 (96–132)
DEL total count 192550 (157937–217782) 202085 (166805–227228) 192550 (157937–227228)
DEL novel rate 23.85% (23%/25%) 23.75% (22%/26%) 23.85% (22%/26%)
Frame-shifting DEL 117 (96–144) 110 (86–126) 117 (86–144)
Frame-preserving DEL 120 (100–138) 115 (106–128) 120 (100–138)
SUB total count 68020 (56179–75040) 69396 (59319–76699) 68020 (56179–76699)
SUB novel rate 34.07% (31%/38%) 33.96% (31%/37%) 34.07% (31%/38%)
Frame-shifting SUB 21 (11–27) 19 (14–26) 21 (11–27)
Frame-preserving SUB 259 (208–320) 252 (225–279) 259 (208–320)
The data represent the average counts from the 31 genomes of Huvariome Core in which the fraction of heterozygous SNPs, inserts, deletions or substitutions are
not found in dbSNP (SNP, INS, DEL, SUB novel). The number of loci where a coding SNV did not result in protein sequence change (Synonymous SNP), number of
loci where a coding SNV resulted in protein sequence change, with no change in size of protein (Missense SNP), number of loci where the single nucleotide
change in coding sequence resulted in a STOP codon (TGA, TAG, or TAA), causing an early termination of protein translation (Nonsense SNP), number of loci
where the single nucleotide change in coding sequence resulted in the change of a STOP codon into a codon that codes for an amino acid, resulting in the
continuation of the translation for this protein (Nonstop SNP), number of loci where the single nucleotide change in coding sequence resulted in the change of a
START codon into a codon for something other than a start codon, likely resulting in a non-functional gene (Misstart SNP). The number of insertion, deletion or
substitution loci where the change in coding sequence resulted in a frameshift for the encoded protein (Frame-shifting INS, DEL, SUB), number loci where there is
a change in coding sequence and the length of the insertion is a multiple of 3, resulting in the insertion of amino acids in the encoded protein in-frame (Frame-
preserving INS, DEL, SUB).
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can be scaled to include any annotation type or source
including the reference genome associated with the ori-
ginal mapped reads from the primary sequencing files.
Annotation is connected to allow for fast updates and mi-
gration, e.g. to NCBI build 37 and meta-data concerning
the individual genomes, and the minimal information de-
fining a phenotype is stored in a sample table (Figure 1).
User interface
Data in Huvariome can be queried and retrieved
through a web interface that allows users to search the
datasets for a specific gene or request information for a
genomic region by means of a list of positions. The user
inputs variations as a tab or space separated list of va-
riation positions in the format chromosome, begin, end
(optional) using a zero based format [18] (Figure 2).
After the query is completed, the results, e.g. a table of
allelic frequencies ordered by position per genetic groupin the Diversity Panel, are returned on a webpage via an
email containing the link to the table. Results for Huva-
riome Core (HVC) include the SNV quality measures
derived from HVC and the Diversity Panel and are
annotated with functional impact derived from
Complete Genomics annotation. The results are add-
itionally annotated with existing genetic variations, regu-
lation features and disease association, as mentioned
above. Registered users can submit a list of genomic
positions to obtain allele frequencies and corresponding
annotation for each of the HVC, the Diversity Panel, a
Disease Cohort (genomes with associated disease pheno-
type), and a Pedigree Cohort (genomes of related indivi-
duals). Guest users can submit a list of genomic
positions to receive the allele frequency for up to fifty
nucleotide positions from the Diversity Panel with the
associated no-call rate (see section Allele No-call rate).
Common annotation, symbol, transcript identifier, the
impact on the gene (gene component), known genomic
Figure 1 Huvariome database schema. The part of the database schema representing the relationship between the core variation and
annotation tables based on the content delivered by Complete Genomics.
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multiple species (VISTA) are provided for each variation
(Figure 3). Variations specific to a population, such as
with the Diversity and Pedigree Panels, are returned as
population specific variations which include the impact
of variation on the coding sequence and associated
dbSNP variants (Figure 3). Users can submit a list ofgenomic positions to receive the allele frequency for up
to one hundred nucleotide positions and corresponding
annotation for the Diversity Panel, the Pedigree Cohorts,
the associated common variation tag (without frequen-
cies from the HVC Panel) and the associated no-call
rate. This functionality is accomplished by storing each
observed variation indexed by both the library to which
Figure 2 Huvariome database access screen. Users can access the system from a central page (http://huvariome.erasmusmc.nl) in which a
genome is chosen and variants to be searched are uploaded as tab or space delimited search requests such that there is one variation per line.
A region is searched by including an end position with the chromosome and start position.
Figure 3 Huvariome genotype frequency page. The output page giving the distribution of allelic variations in the Diversity Panel of genomes
for the European (CEU) and African (ASW) populations. In this example the first ten positions that were queried from the cardiomyopathy data
set from Meder et al. 2011 [25] are shown. Each variant is returned per row with the frequency of each genotype highlighted by the size of the
associated blue bar. Abbreviations: chromosome (chr); 0-based location (pos); reference allele (ref); variant alleles 1 and 2 (a1, a2); indels (ins, del);
substitutions (sub); no-call (unkn.); no-call rate (nc rate); external reference (xref); predicted amino acid change (impact); gene symbol (gsym);
gene component (comp), e.g. exon, intron; and variant from database of genomic variants (dgv).
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which the sequences were aligned. Registered users for
can access their own genomes for study from the same
access page.
Utility
Content and individual characteristics
The Huvariome database currently contains variations
from 165 deep sequenced human genomes, at the time
of writing, obtained with WGS, including tumor and
associated normal genomes, small pedigrees and 42 indi-
viduals representing 10 different populations. The 69 in-
dividual freely available genomes [19] are non-diseased
samples which include a Yoruban trio, a CEPH/Utah
pedigree of 17 family members, a Puerto Rican trio, and
a diversity panel representing nine different populations,
from the Coriell Institute for Medical Research. Samples
were sequenced to an average genome-wide coverage of
about 80X (range of 51X to 89X). Huvariome includes
the additional control dataset, beyond the Diversity and
Pedigree Panel, called Huvariome Core (HVC), which is
a subset of 31 genomes from unrelated individuals with
no detectable disease association. The average coverage
for HVC genomes is 70X with no-call rate of 3.5% and
3.25 million SNVs per individual genome (Table 2). Ad-
ditional quality control analysis includes the calculation
of the transition (Ti) to transversion (Tv) and heterozy-
gous (hetero) to homozygous (homo) SNV ratios for
several genomics features including, coding, intergenic,
intronic, untranslated region, splice sites, transcription
start site and the impact on the resultant protein as syn-
onymous, missense and nonsense changes (Table 3). The
Ti/Tv ratios for synonymous, missense and nonsense












The transition (ti) to transversion (tv) and heterozygous (hetero) to
homozygous (homo) ratios for SNVs were calculated for several regions of the
genome, coding regions (CDS), intergenic, intronic (INTRON), untranslated
region (UTR), splice sites (DONOR and ACCEPTOR), transcription region (TSS),
and for different impact on the resultant protein sequence, no change in
sequence (SYNONYMOUS), a change in the protein sequence with no change
in size of protein (MISSENSE) and an early termination of protein translation
(NONSENSE).genomes which are in agreement with values of 5.6, 2.31
and 2.13 determined by Tennessen et al. 2012 [20]. The
coding and intergenic Ti/Tv for the 31 genomes are 2.99
and 2.07, which are consistent with those published by
Guo et al. 2012 [21] of 2.81 and 2.27 for exonic and
non-exonic regions. The het/homo ratio for the same
regions for HVC, ranges from 1.40-0.97 (Table 3) and
are consistent with previous studies [20].
Allele no-call rate
We used the database to determine the no-call rate of
allele calling at all 3 billion positions in the human ge-
nome. The control genomes are used to calculate a SNV
no-call rate (nc rate) at the base pair level:
nc rate ¼ 1 n
t
 
where n is the number of no-calls (unidentifiable alleles
at the position) and t is the total number of genomes.
The fraction n/t is the proportion of alleles that are not
able to be sequenced at a given base, and it is subtracted
from 1 so that the higher the nc rate, the more plausible
the base is called the correct nucleotide. In other words,
this value indicates how likely the base is able to be
sequenced and can be viewed as a measure of reliability
for the individual base (Figure 3).
Common variants
The minor allele frequency (MAF) for each SNV in
HVC of 31 genomes is calculated as the smaller of the
number of occurrences of a reference allele or its variant
allele divided by the number of samples (n=31) as out-
line by Zhu et al. 2011 [22]. A SNV with a MAF equal
to zero indicates the genotype is the same for all samples
and is subsequently removed whilst the remaining SNVs
are placed into one of 31 MAF bins. The AWclust pack-
age [23] from Bioconductor, which is not included in
Huvariome, was used to determine the similarity of the
all genomes to the HVC samples using a modified input
to match the application. The HVC samples (red) clearly
segregate with the CEU and apart from the African and
Asian populations of the Diversity Panel (Figure 4). The %
of the number of SNVs with a MAF ≤ 5% or > 5% are
91.8% and 8.2% for the Exome Project and 87.4% and
12.4% for the 31 genomes used in Huvariome, providing
evidence of consistency between these CEU study cohorts.
Case study 1: confirmation of polymorphic variation
To identify new polymorphic variants and to demon-
strate how Huvariome can provide an accurate prediction
of rare SNVs we selected a set of 26 non-synonymous
coding SNVs (cSNVs) which were found in one of the
eight genomes sequenced in the study by Ng et al. 2009
[24]. Twenty six cSNVs which were called as potentially
Figure 4 Similarity of HVC to diversity panel. The output from AWClust [23] is shown in a multi-dimensional scaling plot. The genomes of
HVC samples (HuVar), the Chinese and Japanese (CHB, JPT), the African (MKK, ASW, YRI, LWK), the Indian and Mexican (MXL, GIH) and the
European (CEU) populations are shown in this plot. The HVC (HuVar =red) overlap with the CEU population, indicating the samples are more
similar to the European samples than the others.
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these positions (Table 4, [24]) have been analyzed using
Huvariome reference genomes, HVC and Diversity Panel
(Table 2). The genotype for the eight HapMap samples
(International HapMap Consortium, 2003) used in the
study are displayed in the columns beginning with “NA”
and the last three columns represent the genotypes
predicted for each group from the two reference cohorts
in Huvariome (Table 4). Seven of these 26 cSNVs geno-
types are homozygous reference, as determined from
Huvariome and heterozygous in the remaining 19 cases;
the correct allele has been called in all cases (Table 4).
This example demonstrates the value of a high quality
reference cohort to help disambiguate potential false
positive calls from NGS studies.
Case study 2: cardiomyopathy genes
In this example we use the recently described list of
resequenced candidate cardiomyopathy associated
genes [25] to determine the common variants and the
non-polymorphic variants, and therefore candidate car-
diomyopathy genes, in our cohorts. A list of 38 ran-
domly selected variants and 6 variations associated withDCM or HCM which were Sanger sequenced to confirm
their presence in the sample of origin (Table 5 and 5
[25]), were analyzed for allele frequency variation using
Huvariome. Meder et al. 2011 [25] could confirm 86%
of variants by Sanger sequencing and we could predict
normal alleles in 100% of cases with an nc rate (0.0-0.1)
based on the two reference cohorts, Diversity Panel and
HVC. The 30 variants, present in 19 genes, were con-
firmed in Huvariome as being polymorphic with 26 ha-
ving an associated dbSNP number and two of the
polymorphic variants not being present in HVC ge-
nomes (Table 5). The six known variants were anno-
tated in Huvariome (Table 6, HGMD) with Biobase
HGMD and confirmed the prediction, however the re-
verse complement is listed if in Huvariome the gene in
HGMD is on the reverse strand (e.g. MYBP3
47324447C>T is listed as 977G>A in Table 6). An ad-
ditional microdeletion in TNNT2 is present in HGMD
whereas deletion of C was originally observed (Table 6)
[25]. In addition to the six known cardiomyopathy va-
riants there are six novel candidate caridomyopathy va-
riants for which the genomic positions are homozygous
in all 71 reference genomes (Table 6).
Table 4 Confirmation of genotypes from 26 ambiguous variations calls





Gene NA12156 NA12878 NA18507 NA18517 NA19129 NA19240 NA18555 NA18956 Change European African Asian
2 227829345 G ASP,TYR COL4A3 K G G G G G G G K G:T G:T
6 71029714 T GLU,GLY COL9A1 Y T T T T T T T Y T:T T:T T:T
14 70059717 T TYR,CYS ADAM20 Y T T T T T T T Y T:T T:T T:T
16 28511156 T ASN,THR SULT1A2 K T T T T T T T K T:G T:G T:G
9 100837151 C PRO,LEU COL15A1 C Y C C C C C C Y C:C
14 69994396 T TYR,HIS ADAM21 T Y T T T T T T Y T:T T:T T:T
16 28514697 G PRO,LEU SULT1A2 G R G G G G G G R G:A G:A
2 227632472 G PRO,LEU COL4A4 G G R G G G G G R G:A
2 237945216 G ARG,TRP COL6A3 G G R G G G G G R G:A
6 32286548 C GLY,ARG NOTCH4 C C Y C C C C C Y C:T
10 123233227 C ARG,GLN FGFR2 C C Y C C C C C Y C:C C:C C:C
15 72802259 A ILE,THR CYP1A1 A A R A A A A A R A:G
15 82491107 T MET,THR ADAMTSL3 T T Y T T T T T Y T:C
19 46210061 T ILE,THR CYP2B6 T T Y T T T T T Y T:T T:T T:T
4 73407648 C GLY,ARG ADAMTS3 C C C Y C C C C Y C:T
6 46728211 C ARG,PRO CYP39A1 C C C S C C C C S C:G C:G
7 99283117 G ARG,GLN CYP3A43 G G G R G G G G R G:A
10 96474119 G VAL,LEU CYP2C18 G G G K G G G G K G:T
10 96698964 A HIS,ARG CYP2C9 A A A R A A A A R A:G
15 76845583 G PRO,LEU ADAMTS7 G G G R G G G G R G:A
1 120269806 C GLY,ARG NOTCH2 C C C C C Y C C Y C:C C:C C:C
8 24420887 C PRO,LEU ADAM7 C C C C C Y C C Y C:C C:C C:C
17 38961570 G PRO,LEU ETV4 G G G G G G R G R G:A
21 46365928 C PRO,THR COL6A2 C C C C C C M C M C:A
2 189622367 G PRO,LEU COL5A2 G G G G G G G R R G:A
5 129100767 C THR,ILE ADAMTS19 C C C C C C C T T C:T
Results from Huvariome analysis of 26 selected coding SNVs to disambiguate genetic variation determined by Ng et al. 2009 [24]. The first 7 columns display the normal variations and their proposed functional
impact, determined by Ng et al. 2009. The base changes are presented as the IUPAC codes per sample (e.g. NA12156), which are grouped by populations, CEU (NA12156, NA12878), YRI (NA18507, NA18517, NA19129,
NA19240), Asian (NA18555, NA18956), with the impacted bases denoted with bold letters, and in the column titled “change”. The last three columns contain the genotypes called for the three populations present in


















Table 5 Confirmation of known population variation











LMNA 1 154372809 T C Yes T/C dbsnp.83:rs505058
SMYD2 1 212558909 G A Yes G/A dbsnp.86:rs1134647
TTN 2 179163877 G A Yes G/A dbsnp.130:rs72646845
TTN 2 179170739 A G Yes A/G dbsnp.126:rs35833641
TTN 2 179329196 C T Yes C/T dbsnp.116:rs7585334
TTN 2 179337706 C T Yes C/T dbsnp.100:rs2291311
TTN 2 179352280 G A Yes G/A dbsnp.88:rs1552280
HDAC2 6 114372280 C T Yes T/C dbsnp.121:rs13204445
TMEM2 9 73549916 C T Yes C/T dbsnp.72:rs25689
TMEM2 9 73550029 C G Yes G/C dbsnp.107:rs3739783
MYPN 10 69603927 G A No G/A dbsnp.120:rs10997975
LDB3 10 88483707 A T Yes A/T dbsnp.127:rs45567939
TRAF6 11 36473064 T C Yes T/C*
MYBPC3 11 47326019 G A Yes G/A dbsnp.120:rs11570058
MYBPC3 11 47326617 T C Yes T/C dbsnp.107:rs3729989
MYH6 14 22931651 A G Yes A/G dbsnp.80:rs365990
MYH7 14 22968900 G A No G/A dbsnp.86:rs735712
DICER1 14 94626500 A T Yes A/T dbsnp.52:rs13078
ACTC1 15 32868460 G C Yes G/C dbsnp.116:rs8037241
TPM1 15 61138893 C A Yes C/A dbsnp.86:rs1071646
TCAP1 17 35075837 A C Yes A/C dbsnp.86:rs1053651
DSC2 18 26903040 T C Yes T/C**
DSG2 18 27365107 G A Yes G/A
DSG2 18 27376616 G A Yes G/A
TNNI3 19 60357396 A C Yes A/C dbsnp.116:rs7252610
PARVB 22 42726784 T C Yes T/C dbsnp.86:rs1007863
PARVB 22 42821201 T C Yes T/C dbsnp.92:rs1983609
PARVB 22 42821229 T C Yes T/C dbsnp.86:rs738479
DMD X 31406271 C T Yes C/T dbsnp.89:rs1800280
DMD X 32413115 T C Yes T/C dbsnp.79:rs228406
Genomic nucleotide positions 1-based (Reference Position), nucleotides (Reference and Variant Alleles), and Confirmation by Sanger Sequencing are determined
by Meder et al. 2011 [25]. The Variant Alleles in bold are the reference alleles in NCBI build 36. Huvariome Alleles are represented with the NCBI build 36 reference
allele first in the pair (e.g. T/C with T from NCBI build 36). The T/C variant labeled with * is not found in the HVC, but in the CEU and GIH population; the T/C
variant labeled with ** is not found in the HVC, but in the YRI and JPT population.
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In addition to the allele frequencies from HVC, Diversity
and Pedigree Panels, any variant which is known to be
part of a gene is used to search our database germ line
SNV reported for the HVC reference set. We implemented







Where m is the number of exons within a given gene,
vi is the number of variants in exon i, and li is the length
(in base pairs) of exon i. The ratio within parentheses isthe proportion of bases that are variants in exons out of
all bases within the exons of the gene. The negative log
transformation produces a score such that a relatively
small value corresponds to a gene with a large number
of variants per base within the exon. Likewise, a larger
score indicates a gene with a smaller number of variants
per base within the exon. The nine candidate cardio-
myopathy genes from Table 6 were used to search this
resource. The results (Table 7) demonstrate that these
genes have similar mutation rates compared with all
known genes (26,000) listed in the database where the
most variable gene is HLA-DRB6 (rate = 2.1) and the
least is AHNAK (rate = 9.8). These data suggest that
Table 6 Variations in candidate cardiomyopathy genes
Gene
symbol















LMNA 1 154372340 R>Stop C T Yes C/C R321ter + Cardiomyopathy,_dilated|961C>T
TNNT2 1 199599130 E163fs C – No C/C – Cardiomyopathy,_hypertrophic|487G>A
SMYD2 1 212558105 H>Y C T Yes C/C
DSP 6 7525794 R>G C G No C/C Arrhythmogenic_right_ventricular_dysplasia/
cardiomyopathy|4372C>G
TMEM2 9 73505380 T>T C T Yes C/C
ILK 11 6585971 P>L C T No C/C Cardiomyopathy,_dilated|209C>T
MYBPC3 11 47324447 R>Q C T Yes C/C R326Q – Cardiomyopathy,_hypertrophic|977G>A
MYBPC3 11 47313209-47313210 P955fs CT – Yes AG/AG P955fs Cardiomyopathy,_hypertrophic|2864_2865delCT
MYBPC3 11 47321263-47321264 F412fs TT – Yes AA/AA F412fs Cardiomyopathy,_hypertrophic|1235_1236delTT
MYH7 14 22963165 C905fs G – No A/A
MYH7 14 22968054 R>C G A Yes G/G R453C – Cardiomyopathy,_hypertrophic|1357C>A
MYH7 14 22971706 Y>H A G Yes A/A Cardiomyopathy,_hypertrophic|484T>C
MYH7 14 22971762 R>Q C T Yes C/C R143Q – Cardiomyopathy,_hypertrophic|428G>A
Genomic nucleotide positions 1-based (Reference Position), nucleotides (Reference and Variant Alleles), and Confirmation by Sanger Sequencing are determined by Meder et al. 2011 [25]. Huvariome alleles are
represented with the NCBI build 36 reference allele first in the pair (e.g. T/C with T from NCBI build 36). Variants that have previously been found to be associated with cardiomyopathy are denoted by Known
Pathological Variant [25] and cardiomyopathy variations derived from the professional edition of Human Gene Mutation Database (HGMD) were supplied by Biobase. The HGMD descriptions in bold are linked to the

















Table 7 Rate of reference genome variation in candidate
cardiomyopathy genes
Gene symbol Ref var count Exon length (bp) Rate (r) Var count
TNNT2 2 1153 6.4 1
LMNA 5 3225 6.5 1
SMYD2 2 1685 6.7 1
TMEM2 6 6523 7.0 1
MYH7 5 6030 7.1 4
DSP 7 9730 7.2 1
ILK 1 1797 7.5 1
MYBPC3 2 4218 7.7 5
This table displays the number of variations in the genes that are used for
searching Huvariome (Var count), the expected number of variants in the 31
genomes of HVC (Ref var count), the cumulative exon length in bp and the
resultant rate of variants within the exons (negative log).
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paralogs and add support that these variations (Table 6)
are associated with cardiomyopathy candidate genes.
Discussion
Huvariome was developed utilizing Oracle 11i techno-
logy designed to run on the Oracle Exadata platform
[26], which was selected based on a number of favorable
characteristics including scalability (Exadata scales
linearly with added hardware) and performance (smart
scans and hybrid columnar compression providing deep
compression) [27]. This ensures that data do not need to
be replicated as in a de-normalized data delivery plat-
form such as Biomart [28] in which the data in the pri-
mary tables must be transformed and thus replicated to
deliver fast return of results.
WGS was chosen as a basis for Huvariome to pro-
vide research scientists and the research community with
a reference cohort for allele frequencies and for base
quality checking at any position in the human genome.
Here the database is presented as a resource for priori-
tizing rare SNVs identified with NGS technology. In
contrast to other projects, only high coverage genome
sequences are used and no imputation has been per-
formed to infer unsequenced variants. Huvariome has
been successfully used to prioritize candidate cancer
targets and genomic variations detected in familial con-
genital malformations [29].
The system has been developed to address the need to
access genetic variation frequency and assigned prob-
ability in control population datasets (e.g. to determine
the frequency of a change in the population) and to per-
form aggregate analyses and assign validation probabi-
lities to observed, naturally occurring variants based on
sequencing characteristics across a population. To sup-
port these goals we have included the common variation
determined in a reference population representative ofthe Benelux population as part of the output from the
public reference datasets provided. In addition we have
used the common variations present in HuVariome Core
and the Diversity panel to determine the allele “no-call”
rate per base of the human genome. We have demon-
strated the ability of Huvariome to determine the va-
riants in another resequencing project [24] and to
support candidate gene selection in a cardiomyopathy
resquencing project [25].
Conclusions
Huvariome was developed to facilitate data storage of
WGS and the analysis of genetic variation detected by
WGS in research and clinical diagnostics environment,
which both require a secure and scalable database.
Huvariome provides a user-friendly interface to access
genetic variation data from diverse cohort studies for
the identification of disease-promoting variations in the
underlying database. The variants are annotated to pro-
vide users with a wealth of information that they would
otherwise have to retrieve manually. The use of high
depth and low error whole genome sequencing ensures
a high accuracy of allele calling, and the no-call rate
offers additional information about the allele frequencies
at each base in the human genome build. The database
is currently used for several tasks including SNV disco-
very and in silico validation. Since Huvariome contains
data from experiments as well as from reference cohorts,
we can separate rare polymorphisms from candidate
disease-causing variants. Access to variations obtained
from the public Diversity Panel data is freely available
from the Huvariome web site. The examples show that
Huvariome is a powerful application to confirm ambi-
guous genotype calls with the associated no-call per base
of the human genome. The application allows users to
easily compare their genotypes with the 69 reference
genomes of the Diversity Panel and Pedigrees to
prioritize the candidate gene selection for both family
and tumor-based genome analysis. The use of Huva-
riome Core samples provide additional support to deter-
mine if a variant is common (or rare), if the gene that is
a candidate has an excess of variations beyond what is
statistically expected if a variant is common, and the no-
call rate associated with sequencing any base in the
reference genome. This application has been successfully
used in candidate gene selection for both tumor profi-
ling and Mendelian inheritance studies [29].
We are currently enhancing the performance and sca-
lability by migrating this application to run on Oracle
Exadata hardware, allowing highly optimized parallel
processing and high compression capability for cheaper
storage and faster querying [27], and are developing
summary pages that include visualizations using TIBCO
Spotfire Web Player technology [30]. The data loaders
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modate changes in data format thereby making the data-
base sequencing platform independent which will allow
sequencing results from other NGS platform (e.g. Illumina,
Roche, Life Technologies) and data types (e.g. RNAseq) to
be incorporated into this database.
We encourage collaborators to upload their own va-
riants files into the knowledge archive initially in colla-
boration with the Erasmus University Medical Center
and in the future via an optimized upload website with
an agreed policy and standardized format and to ensure
that the data quality is maintained.
Availability
Huvariome is freely accessible for use from the web site
at URL: http://huvariome.erasmusmc.nl.
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